Koshlan Mayer-Blackwell

Koshlan Mayer-Blackwell

Auto-generated profile, based on publicly available information

Koshlan Mayer-Blackwell

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2021 in eLife
Verified
Journal Article
Open access
KMKoshlan Mayer-Blackwell
Koshlan Mayer-Blackwell
SSStefan Schattgen
Stefan Schattgen
LCLiel Cohen-Lavi
Liel Cohen-Lavi
JCJeremy C Crawford
Jeremy C Crawford
ASAisha Souquette
Aisha Souquette
AFAndrew Fiore-Gartland
Andrew Fiore-Gartland
T-cell receptors (TCRs) encode clinically valuable information that reflects prior antigen exposure and potential future response. However, despite advances in deep repertoire sequencing, enormous TCR diversity complicates the use of TCR clonotypes as clinical biomarkers. We propose a new framework that leverages experimentally inferred antigen-associated TCRs to form meta-clonotypes – groups of biochemically similar TCRs – that can be used to robustly quantify functionally similar TCRs in bulk repertoires across individuals. We apply the framework to TCR data from COVID-19 patients, generating 1831 public TCR meta-clonotypes from the SARS-CoV-2 antigen-associated TCRs that have strong evidence of restriction to patients with a specific human leukocyte antigen (HLA) genotype. Applied to independent cohorts, meta-clonotypes targeting these specific epitopes were more frequently detected in bulk repertoires compared to exact amino acid matches, and 59.7% (1093/1831) were more abundant among COVID-19 patients that expressed the putative restricting HLA allele (false discovery rate [FDR]<0.01), demonstrating the potential utility of meta-clonotypes as antigen-specific features for biomarker development. To enable further applications, we developed an open-source software package, tcrdist3, that implements this framework and facilitates flexible workflows for distance-based TCR repertoire analysis.

13 February 2026 in Science Advances
Verified
Journal Article
Open access
Puneet RawatPuneet Rawat
Puneet Rawat
MSMelanie Shapiro
Melanie Shapiro
LPLeeana D. Peters
Leeana D. Peters
MWMichael Widrich
Michael Widrich
KMKoshlan Mayer-Blackwell
Koshlan Mayer-Blackwell
TBTodd Brusko
Todd Brusko
Type 1 diabetes (T1D) is a T cell–mediated disease with a strong immunogenetic human leukocyte antigen (HLA) dependence. HLA allelic influence on the T cell receptor (TCR) repertoire shapes thymic selection and controls activation of diabetogenic clones yet remains largely unresolved in T1D. We sequenced the circulating TCRβ chain repertoire from 2250 HLA-typed participants across three cross-sectional cohorts, including individuals with T1D and healthy related and unrelated controls. We found that HLA risk alleles show higher restriction of TCR repertoires in individuals with T1D. We leveraged deep learning to identify T1D-associated TCR subsequence motifs that were also observed in independent TCR cohorts residing in pancreas-draining lymph nodes of individuals with T1D. Collectively, our data demonstrate T1D-related TCR motif enrichment based on genetic risk, offering a potential metric for autoreactivity and groundwork for TCR-based diagnostics and therapeutics.

26 December 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
KMKoshlan Mayer-Blackwell
Koshlan Mayer-Blackwell
SSStefan Schattgen
Stefan Schattgen
LCLiel Cohen-Lavi
Liel Cohen-Lavi
JCJeremy Chase Crawford
Jeremy Chase Crawford
ASAisha Souquette
Aisha Souquette
AFAndrew Fiore-Gartland
Andrew Fiore-Gartland
As the mechanistic basis of adaptive cellular antigen recognition, T cell receptors (TCRs) encode clinically valuable information that reflects prior antigen exposure and potential future response. However, despite advances in deep repertoire sequencing, enormous TCR diversity complicates the use of TCR clonotypes as clinical biomarkers. We propose a new framework that leverages antigen-enriched repertoires to form meta-clonotypes – groups of biochemically similar TCRs – that can be used to robustly identify and quantify functionally similar TCRs in bulk repertoires. We apply the framework to TCR data from COVID-19 patients, generating 1831 public TCR meta-clonotypes from the 17 SARS-CoV-2 antigen-enriched repertoires with the strongest evidence of HLA-restriction. Applied to independent cohorts, meta-clonotypes targeting these specific epitopes were more frequently detected in bulk repertoires compared to exact amino acid matches, and 59.7% (1093/1831) were more abundant among COVID-19 patients that expressed the putative restricting HLA allele (FDR < 0.01), demonstrating the potential utility of meta-clonotypes as antigen-specific features for biomarker development. To enable further applications, we developed an open-source software package, tcrdist3 , that implements this framework and facilitates flexible workflows for distance-based TCR repertoire analysis.

12 December 2024 in medRxiv
Verified
Preprint
Open access
PDF file
Puneet RawatPuneet Rawat
Puneet Rawat
MSMelanie Shapiro
Melanie Shapiro
LPLeeana D. Peters
Leeana D. Peters
MWMichael Widrich
Michael Widrich
KMKoshlan Mayer-Blackwell
Koshlan Mayer-Blackwell
TBTodd Brusko
Todd Brusko
Type 1 Diabetes (T1D) is a T-cell mediated disease with a strong immunogenetic HLA dependence. HLA allelic influence on the T cell receptor (TCR) repertoire shapes thymic selection and controls activation of diabetogenic clones, yet remains largely unresolved in T1D. We sequenced the circulating TCRβ chain repertoire from 2250 HLA-typed individuals across three cross-sectional cohorts, including T1D patients, and healthy related and unrelated controls. We found that HLA risk alleles show higher restriction of TCR repertoires in T1D individuals. We leveraged deep learning to identify T1D-associated TCR subsequence motifs that were also observed in independent TCR cohorts residing in pancreas-draining lymph nodes of T1D individuals. Collectively, our data demonstrate T1D-related TCR motif enrichment based on genetic risk, offering a potential metric for autoreactivity and basis for TCR-based diagnostics and therapeutics.

1 July 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
MSMaria T. Søgaard
Maria T. Søgaard
DTDiane Tseng
Diane Tseng
SGSarah Gibbs
Sarah Gibbs
WWWei Wu
Wei Wu
LNLorna G. Nolan
Lorna G. Nolan
VNViswam S Nair
Viswam S Nair
The blood T-cell receptor (TCR) repertoire broadly reflects current and lifetime immune responses against infectious pathogens and cancer, but the circulating T-cell repertoire remains a largely untapped resource for cancer biomarker studies due to repertoire complexity and limited profiling data. In this study, we investigated the use of blood TCR sequencing for the early detection of lung cancer. We sequenced the leukocyte fraction of peripheral blood from 633 individuals divided into a case–control cohort (n = 511) and a lung cancer screening cohort (n = 122), representing more than 12.6 million unique clonotypes. Based on the TCR repertoires in these individuals, we devised a Tumor Immune Lymphocyte Score (TILS) using either TCR specificity groups (TILS-A) or highly recurrent “public” TCR clonotypes (TILS-B) capable of detecting lung cancer. TILS-A consisted of 125 TCR specificity groups that outperformed the TILS-B classifier of 49 public, TCRβ-Vβ–defined clonotypes for cancer detection. TILS classifiers (TILS-A and TILS-B) provided predictive value after accounting for age, smoking status, and nodule size in the lung cancer screening cohort and improved cancer prediction for individuals with indeterminate lung cancer risk. In the subgroup analysis, TILS-A was associated with lung cancer in both early- and late-stage disease, had improved accuracy when accounting for HLA status, and was validated in an external dataset studying lung cancer initiation. Collectively, these data suggest that profiles of the circulating T-cell response can provide value for lung cancer detection and support its use as a diagnostic tool.

16 January 2026 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
KMKoshlan Mayer-Blackwell
Koshlan Mayer-Blackwell
AMAnastasia Minervina
Anastasia Minervina
MPMikhail Pogorelyy
Mikhail Pogorelyy
Puneet RawatPuneet Rawat
Puneet Rawat
MSMelanie Shapiro
Melanie Shapiro
AFAndrew Fiore-Gartland
Andrew Fiore-Gartland
T cell receptors (TCRs) recognize peptides presented by polymorphic human leukocyte antigen (HLA) molecules, but HLA genotype data are often missing from TCR repertoire sequencing studies. To address this, we developed TCR2HLA, an open-source tool that infers HLA genotypes from TCRβ repertoires. Expanding on work linking public TRBV-CDR3 sequences to HLA genotypes, we incorporated “quasi-public” metaclonotypes – composed of rarer TCRβ sequences with shared amino acid features – enriched by HLA genotypes. Using four TCRβseq datasets from 3,150 individuals, we applied TRBV gene partitioning and locality-sensitive hashing to identify ~96,000 TCRβ features strongly associated with specific HLA alleles from 71M input TCRs. Binary HLA classifiers built with these features achieved high balanced accuracy (>0.9) across common HLA-A (9/12), B (9/12), C (6/13), DRB1 (11/11) alleles and prevalent DPA1/DPB1 (6/10), DQA1/DQB1 (8/17) heterodimers. We also introduced a high-sensitivity calibration to support predictions in samples with as few as 5,000 unique clonotypes. Calibrated predictions with confidence filtering improved reliability. Beyond genotype imputation, TCR2HLA enables the discovery of novel HLA- and exposure-associated TCRs, as shown by the identification of SARS-CoV-2 related TCRs in a large COVID-19 dataset lacking HLA data. TCR2HLA provides a scalable framework for bridging the gap between TCRseq data and HLA genotype for biomarker discovery.